|
Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
|
2
|
Resverlogix Corp.
|
Apr 18, 2019 02:55PM
|
|
Re: Resverlogix's Twitter Account....
|
2
|
Resverlogix Corp.
|
Nov 05, 2017 04:02PM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
4
|
Resverlogix Corp.
|
Dec 02, 2019 10:55AM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
4
|
Resverlogix Corp.
|
Dec 02, 2019 11:46AM
|
|
Re: Resverlogix Special Meeting Jun 30 9am MDT
|
6
|
Resverlogix Corp.
|
Jul 01, 2015 11:28AM
|
|
Re: Resverlogix Special Meeting Jun 30 9am MDT
|
4
|
Resverlogix Corp.
|
Jul 01, 2015 11:35AM
|
|
Re: Resverlogix Repays $68.8 Million Loan
|
1
|
Resverlogix Corp.
|
Dec 07, 2017 12:00PM
|
|
Re: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
|
4
|
Resverlogix Corp.
|
May 15, 2017 05:17PM
|
|
Re: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
|
5
|
Resverlogix Corp.
|
May 30, 2017 11:13AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 05:45PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
4
|
Resverlogix Corp.
|
Jun 22, 2020 05:54PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:10PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:27PM
|
|
Re: Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
|
3
|
Resverlogix Corp.
|
Jul 10, 2017 03:20PM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
4
|
Resverlogix Corp.
|
Oct 04, 2023 01:25PM
|
|
Re: Resverlogix NYAS Symposium notes
|
1
|
Resverlogix Corp.
|
Apr 30, 2016 09:36AM
|
|
Re: Resverlogix NYAS Symposium notes
|
2
|
Resverlogix Corp.
|
Apr 29, 2016 03:06PM
|
|
Re: Resverlogix is looking at issuing some none tradable financial instruments
|
3
|
Resverlogix Corp.
|
Sep 06, 2015 10:20AM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
9
|
Resverlogix Corp.
|
Nov 02, 2021 12:19PM
|
|
Re: Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
|
5
|
Resverlogix Corp.
|
Jul 26, 2017 06:28PM
|
